Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country

References

• Lee VHF, Mok TSK, Goto Y., et al. Differences between the east and the west in managing advanced-stage non-small cell lung cancer. Clin Oncol. 2020;32(1):e1–e9. doi:10.1016/j.clon.2019.07.014
   Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–4283. doi:10.1158/1078-0432.CCR-08-0168
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23. doi:10.1038/nrc2291
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–1111. doi:10.1200/JCO.2012.44.5353
   PubMed Web of Science ®Google Scholar
• Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014;6:423–432. doi:10.2147/CLEP.S69718
   PubMed Web of Science ®Google Scholar
• Desai A, Mohammed T, Rakshit S, Krull J. The landscape of ALK alterations in non-small cell lung cancer. J Thorac Oncol. 2021;16(suppl_4):S704–S710. doi:10.1016/S1556-0864(21)01863-3
   Google Scholar
• Chang GC, Yang TY, Chen KC, et al. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep. 2020;10(1):21063. doi:10.1038/s41598-020-78152-1
   PubMed Web of Science ®Google Scholar
• Kozuma Y, Toyokawa G, Seto T. ALK testing methods: is there a winner or loser? Expert Rev Anticancer Ther. 2019;19(3):237–244. doi:10.1080/14737140.2019.1562343
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Banna G, Patel S, Addeo A. Diagnosis and treatment of ALK aberrations in metastatic NSCLC. Curr Treat Options Oncol. 2019;20(10):79. doi:10.1007/s11864-019-0675-9
   PubMed Web of Science ®Google Scholar
• McLeer-Florin A, Duruisseaux M, Pinsolle J, et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer. 2018;116:15–24. doi:10.1016/j.lungcan.2017.12.004
   PubMed Web of Science ®Google Scholar
• Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26(12):1545–1553. doi:10.1038/modpathol.2013.87
   PubMed Web of Science ®Google Scholar
• Mohamad N, Jayalakshmi P, Rhodes A, et al. Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung. Br J Biomed Sci. 2017;74(4):176–180. doi:10.1080/09674845.2017.1331520
   PubMed Web of Science ®Google Scholar
• Doshi S, Ray D, Stein K, et al. Economic analysis of alternative strategies for detection of ALK rearrangements in non small cell lung cancer. Diagnostics. 2016;6(1):4. doi:10.3390/diagnostics6010004
   Web of Science ®Google Scholar
• Elliott J, Bai Z, Hsieh SC, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PLoS One. 2020;15(2):e0229179. doi:10.1371/journal.pone.0229179
   PubMed Web of Science ®Google Scholar
• Thongprasert S, Permsuwan U. Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. Curr Med Res Opin. 2017;33(5):955–961. doi:10.1080/03007995.2017.1297929
   PubMed Web of Science ®Google Scholar
• Lin HM, Pan X, Hou P, et al. Economic burden in patients with ALK+ non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. J Med Econ. 2022;23(8):894–901. doi:10.1080/13696998.2020.1762620
   Web of Science ®Google Scholar
• Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014;9(5):631–638. doi:10.1097/JTO.0000000000000115
   PubMed Web of Science ®Google Scholar
• Patel A, Batra U, Prasad KT, et al. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India. Curr Probl Cancer. 2020;44(3):100571. doi:10.1016/j.currproblcancer.2020.100571
   PubMed Web of Science ®Google Scholar
• Britschgi C, Addeo A, Rechsteiner M, et al. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol. 2020;10:1299. doi:10.3389/fonc.2020.01299
   PubMed Web of Science ®Google Scholar
• Blumenthall GM, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small cell lung cancer. Ann Oncol. 2019;30(5):830–838. doi:10.1093/annonc/mdz060
   PubMed Web of Science ®Google Scholar
• Liu SV, Hu X, Li Y, Burke T, Piperdi B. 108P - Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(suppl_4):S748–S7802. doi:10.1016/S1556-0864(21)01950-X
   Web of Science ®Google Scholar
• Velcheti V, Hu X, Piperdi B, Burke T. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. Sci Rep. 2021;11:9222. doi:10.1038/s41598-021-88453-8
   PubMed Web of Science ®Google Scholar
• Reynolds C, Masters ET, Black-Shinn J, et al. Real-world use and outcomes of ALK-positive crizotinib-treated metastatic NSCLC in US community oncology practices: a retrospective observational study. J Clin Med. 2018;7(6):129. doi:10.3390/jcm7060129
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177. doi:10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Jahanzeb M, Lin HM, Pan X, et al. Real-world treatment patterns and progression-free survival associated with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor therapies for ALK+ non-small cell lung cancer. Oncologist. 2020;25(10):867–877. doi:10.1634/theoncologist.2020-0011
   PubMed Web of Science ®Google Scholar
• Noronha V, Ramaswamy A, Patil VM, et al. ALK positive lung cancer: clinical profile, practice and outcomes in a developing country [published correction appears in PLoS One. 2016 Dec 9; 11(12): e0168221]. PLoS One. 2016;11(9):e0160752. doi:10.1371/journal.pone.0160752
   PubMed Web of Science ®Google Scholar
• Malapelle U, Rossi A, Bria E. Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing? J Thorac Dis. 2019;11(Suppl 15):S1837–S1840. doi:10.21037/jtd.2019.08.99
   PubMedGoogle Scholar
• Gounant V, Duruisseaux M, Soussi G, et al. Does very poor performance status systematically preclude single agent anti-PD-1 immunotherapy? A multicenter study of 35 consecutive patients. Cancers. 2021;13(5):1040. doi:10.3390/cancers13051040
   PubMed Web of Science ®Google Scholar
• Gibson AJW, Box A, Dean ML, et al. Retrospective real-world outcomes for patients with ALK-rearranged lung cancer receiving ALK receptor tyrosine kinase inhibitors. JTO Clin Res Rep. 2021;2:100157. doi:10.1016/j.jtocrr.2021.100157
   PubMedGoogle Scholar
• Wang L, Wang W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review). Oncol Rep. 2021;45(1):13–28. doi:10.3892/or.2020.7851
   PubMed Web of Science ®Google Scholar
• Pennell NA, Mutebi A, Zhou ZY, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1–9. doi:10.1200/PO.18.00356
   PubMed Web of Science ®Google Scholar
• Haratake N, Seto T, Takamori S, et al. Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thorac Cancer. 2019;10:1779–1787. doi:10.1111/1759-7714.13143
   PubMed Web of Science ®Google Scholar
• Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Lung cancer in Malaysia. J Thorac Oncol. 2020;15(3):317–323. doi:10.1016/j.jtho.2019.10.021
   PubMed Web of Science ®Google Scholar
• Lin HM, Wu Y, Yin Y, et al. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clin Lung Cancer. 2022;22:213.
   Google Scholar
• How SH, Tho LM, Liam CK, et al. Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country. Thorac Cancer. 2022;13(11):1676–1683. doi:10.1111/1759-7714.14442
   PubMed Web of Science ®Google Scholar